A UK/Canada Collaboration on the genetics of long-term diabetes complications and their risk factors among people with type 1 diabetes

英国/加拿大就 1 型糖尿病患者长期糖尿病并发症的遗传学及其危险因素开展合作

• 批准号: 409967
• 负责人: Paterson Andrew D
• 金额: $ 32.78万
• 依托单位: Hospital for Sick Children (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-09-01 至 2022-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=409967&lang=en
• 关键词: C-Peptide; Cardiovascular Disease; Genetics; Hba1c; Nephropathy; Retinopathy; Type 1 Diabetes

Over 100,000 Canadians have type 1 diabetes. People with type 1 diabetes require lifelong insulin injections to replace insulin synthesized by specialized cells in their pancreas that have died due to an immune process. Currently there are few treatments

超过10万加拿大人患有1型糖尿病。1型糖尿病患者需要终身注射胰岛素，以取代胰腺中因免疫过程而死亡的专门细胞合成的胰岛素。目前几乎没有治疗方法